

# STATE OF WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES BUREAU FOR MEDICAL SERVICES



#### Office of Pharmacy Service Prior Authorization Criteria

Afinitor<sup>®</sup> and Afinitor Disperz<sup>®</sup> (everolimus)

Prior Authorization Request Form

### Prior authorization requests for Afinitor will be approved if the following criteria are met:

- Approvable for members 18 years of age or older with a diagnosis of advanced renal cell carcinoma (kidney cancer) who have failed therapy with sunitinib (Sutent) or sorafenib (Nexavar); or
- 2. Approvable for members 1 year of age or older with a diagnosis of subependymal giant cell astrocytoma (SEGA) associated with tubular sclerosis complex (TSC) who are not candidates for curative surgical resection; **or**
- 3. Approvable for members 18 years of age or older with a diagnosis of renal angiomyolipomas associated with tubular sclerosis complex (TSC) who do not require immediate surgery; **or**
- Approvable for members 18 years of age or older with a diagnosis of progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic; or
- Approvable for postmenopausal woman with a diagnosis of advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane (Aromasin) after failure of treatment with letrozole (Femara) or anastrozole (Arimidex).

## Prior authorization requests for Afinitor Disperz will be approved if the following criteria are met:

Approvable for members with a diagnosis of subependymal giant cell astrocytoma (SEGA) associated with tubular sclerosis complex (TSC) who are not candidates for curative surgical resection. Members older than 10 years of age must be unable to swallow solid dosage forms (tablets) in order for the Disperz formulation to be approved.

#### References

Afinitor package insert. Indications and usage. Novartis Pharmaceuticals. 7/2014 http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf

Reviewed and Approved Drug Utilization Review Board September 17<sup>th</sup>, 2014